secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001079973-25-001264
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance
---------------------------------------------------------------------------

- Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.
- Net loss $17.0M vs $15.5M; diluted EPS $(0.15) vs $(0.17); Adjusted EBITDA $(4.1)M vs $(8.7)M.
- Pharmacy revenue $62.6M with >$11M gross profit; over 40% YoY growth.
- Expanding capitated partnership with Elevance into two new Florida counties (more than double lives) and with Silver Summit in Nevada.
- Reaffirms full-year 2025 guidance; expects revenue at high end of range and positive Adjusted EBITDA by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325001264/0001079973-25-001264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325001264/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-25-001264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer